Alisha Holtzhausen

8PUBLICATIONS
33CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersInnate immunityMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 12, 2025
PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy.

Nestor Prieto-Dominguez, Paran Goel, Oluwagbemiga A Ojo

|Jul 08, 2024
MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming.

Eden Y Zewdie, George M Edwards, Debra M Hunter

|May 10, 2024
A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression.

Michael P Plebanek, Yue Xue, Y-Van Nguyen

|Nov 23, 2022
Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy.

Balamayooran Theivanthiran, Nagendra Yarla, Tarek Haykal

|Oct 13, 2021
Overcoming Immunotherapy Resistance by Targeting the Tumor-Intrinsic NLRP3-HSP70 Signaling Axis.

Balamayooran Theivanthiran, Tarek Haykal, Linda Cao

|Aug 28, 2019
TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.

Alisha Holtzhausen, William Harris, Eric Ubil

Pageof 2